Zealand Pharma A/S
Smedeland 26 B
Glostrup
DK-2600
Tel: 45-43-28-12-00
Fax: 45-43-28-12-12
Website: http://www.zp.dk/
Email: info@zp.dk
299 articles about Zealand Pharma A/S
-
Positive Phase I Data for Zealand Pharma 's ZP1848 in Crohn's Disease
10/15/2010
-
Sanofi-Aventis (France) Announce Partner Zealand Pharma Has Positive Study Findings from Lixisenatide in First Phase III Get Goal Trial for Type 2 Diabetes
9/20/2010
-
Zealand Pharma Announces An Extension Of The Lixisenatide Global Licensing Agreement With Sanofi-Aventis K.K. For Type-2 Diabetes
6/8/2010
-
Zealand Pharma : Annual Review for 2009
5/6/2010
-
Positive Phase III Diabetes Data with Lixisenatide Announced by Zealand Pharma 's Partner Sanofi-Aventis (France)
4/15/2010
-
Zealand Pharma Announces Augmentation of its Management Team as it Continues its Growth Strategy
3/8/2010
-
Sanofi-Aventis (France) May Take Stake in Zealand Pharma for up to $143 Million
12/23/2009
-
Zealand Pharma Advances A New Generation Of Type 2 Diabetes Treatment
9/1/2009
-
Vyteris, Inc. and Zealand Pharma Announce Agreement on Active Transdermal Patch for Peptide Drugs
4/14/2009
-
Vyteris, Inc. and Zealand Pharma Announce Agreement on Active Transdermal Patch for Peptide Drugs
4/14/2009
-
Zealand Pharma Receives Frost & Sullivan 2008 European Research & Development Award
3/18/2009
-
Helsinn Healthcare SA Announces Partnering Agreement for ZP1846, a Novel GLP-2 Agonist from Zealand Pharma
12/11/2008
-
Zealand Pharma and Helsinn Healthcare SA Sign a €140 Million (US$176.8 Million) Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
12/2/2008
-
Zealand Pharma Appoints New Chief Executive Officer
8/28/2008
-
Phase III Program for AVE0010/ZP10 Licensed From Sanofi-Aventis (France) will Begin in the First Quarter of 2008
2/12/2008
-
Wyeth and Zealand Pharma Advance the First Orally Available Gap Junction Modifier into Phase I Clinical Trials
10/10/2007
-
FDA Has Approved Zealand Pharma 's Investigative New Drug Application (IND) for ZP1846 to Be Administered in Humans; ZP1846 Is Developed for the Prevention and Treatment of Severe Diarrhoea Induced by Chemotherapy
9/6/2007
-
Zealand Pharma Enters Into Expanded Collaboration Agreement With Wyeth Pharmaceuticals (New Jersey)
3/4/2005
-
ConjuChem
4/19/2004